Relmada Therapeutics, Inc. (RLMD): R&D Expense
$26.88M
Year ended 2025-12-31
$28.59M
Trailing 12 months to 2026-06-30
-38.1%
3-year compound annual growth
-5.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.88M | -41.8% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $46.18M | -15.7% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $54.81M | -51.6% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $113.32M | +25.1% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $90.62M | +151.9% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $35.97M | +357.7% | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | $7.86M | n/a | 2021-03-24, From 2019-01-01 |
| No annual figure between 2018-06-30 and 2019-12-31. | |||
| 2018-06-30 | $2.94M | +127.5% | 2019-09-24, From 2017-07-01 |
| 2017-06-30 | $1.29M | -79.2% | 2018-09-28, From 2016-07-01 |
| 2016-06-30 | $6.21M | -21.2% | 2017-09-28, From 2015-07-01 |
| 2015-06-30 | $7.87M | n/a | 2016-09-09, From 2014-07-01 |
| No annual figure between 2013-12-31 and 2015-06-30. | |||
| 2013-12-31 | $5.25M | n/a | 2015-09-11, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $26.88M | -41.8% |
| Journey Medical Corp (DERM) | 2025-12-31 | $480.0K | -95.1% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $7.76M | +138.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $5.76M | -51.6% |
| Dogwood Therapeutics, Inc. (DWTX) | 2025-12-31 | $21.87M | +519.3% |
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $17.86M | +54.7% |
Compare RLMD, DERM, ABUS, ETON side by side · Screen every company in Pharmaceutical Preparations ↗